Titrating lovaza from 4 to 8 to 12 grams/day in patients with primary hypertriglyceridemia who had triglyceride levels >500 mg/dl despite conventional triglyceride lowering therapy

Table 5 TG and Non-HDLC in 7 subjects, where the Lovaza sequence was 4, 8, 12, 4, 4, 4, 4 g/day

Visit	Dosage (g/day)	TG (mg/dl)				Non-HDLC (mg/dl)
Visit	Dosage (g/day)	Mean ± SD	median	% change, p vs Visit 0	p* (vs former Visit)	Mean ± SD	median	% change, p vs Visit 0	p* (vs former Visit)
0	0	1075 ±525	857			245 ±88	214
1	4	672 ±247	587	−37%, .006		217 ±62	223	−11%,
2	8	577 ±189	666	−46%, .0009	NS	203 ±44	199	−17%, .01	NS
3	12	428 ±184	443	−60%, <.0001	.03	192 ±61	164	−22%, .003	NS
4	4	561 ±244	554	.0006	.03	203 ±49	185	.01	NS
5	4	538 ±115	593	.0004		205 ±44	233	.01
6	4	459 ±171	502	<.0001		189 ±31	185	.001
7	4	430 ±191	395	<.0001		171 ±43	164	.0002
		TG decreasing slope during the first 3 months, when the Lovaza dose was increased from 0 to 12 g/day, p=.0018				Non-HDLC decreasing slope during the first 3 months, when the Lovaza dose was increased from 0 to 12 g/day, p=.016

p: comparison of Least-square means using Mixed model.
p*: paired Wilcoxon test for the change from Visit 1 to Visit 2 (dosage from 4 g/day to 8); from Visit 2 to Visit 3 (dosage from 8 g/day to 12); from Visit 3 to Visit 4 (dosage from 12 g/day to 4).